Tag: Boehringer Ingelheim

Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for.

BI and University of Dundee Extend Anti-Cancer Alliance

cancer treatment
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing protei...

BI and Eli Lilly Announced Detailed Findings from the CAROLINA® Trials

Boehringer Ingelheim and Eli Lilly and Company announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk compared with glime...

FDA Accepted Boehringer, Lilly NDA for Triple Combination Tablet for Adults with Type 2 Diabetes

diabetes drugs
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended relea...

BI, Constantia Flexibles to Provide Augmented Reality Packaging Experience

boehringer-ingelheim
Boehringer Ingelheim has partnered with Constantia Flexibles to provide veterinarians and horse owners with Constantia Interactive, an innovative packaging solution which enhances the Nutraxin packagi...

Digital Healthcare Program in Kenya Launched by BI and PharmAccess

boehringer
Using mobile technology to break access and awareness barriers in hypertension and diabetes: that is what the new ‘Tiba Yako’ program strives for. The initiative was launched recently in Nairobi, Keny...

BI and Gubra to Collaborate to Develop Anti-Obesity Peptide Poly-Agonists

boehringer-ingelheim
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gura’s established expe...

BI to Set Up First Industry-Academia-Research Exchange Platform

Boehringer Ingelheim and Harbin Veterinary Research Institute (HVRI), subordinated to the Chinese Academy of Agricultural Sciences (CAAS), jointly unveiled the first ‘industry-academia-research’ excha...

BI’s Angels Initiative Created Network of 1500 European Stroke-Ready Clinics

boehringer
The Angels Initiative announced at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Eu...

Boehringer Ingelheim Published New Data in Rare Disease

preclinical-research
Boehringer Ingelheim announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis associated i...

Boehringer Ingelheim’s SENSCIS® Phase III Trials Met Primary Endpoint

Boehringer Ingelheim announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis associated i...

AbbVie and Boehringer Ingelheim Resolve HUMIRA® U.S. Patent Litigation

patents
AbbVie announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant Boehringer Ingelheim a non-exclusive lice...

PureTech Health Announced Partnership with Boehringer Ingelheim on Cancer Immunotherapies

boehringer
PureTech Health plc (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that it has entered into ...

Boehringer Ingelheim Completed Major Investment for Respiratory Diseases

Just as the next-generation Respimat® inhaler hits the first European markets, Boehringer Ingelheim has completed the investment of €105 million to expand associated production operations at its sites...

Boehringer Ingelheim Seeks Approval of FDA and EMA for SSc-ILD Drug

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibr...

Boehringer Ingelheim and GNA Partner to Fight ASF

Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test. The test would ...

Boehringer Ingelheim Collaborates with 3BP for Drug DIscovery

3B Pharmaceuticals GmbH (3BP), a private German biotechnology company announced a multi-year collaboration in the field of peptide-led drug discovery with Boehringer Ingelheim. Under the agreement,...